Hope Tribune

Choroideremia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

 Breaking News
  • No posts were found

Choroideremia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

June 07
18:38 2021
Choroideremia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

Choroideremia Pipeline

Choroideremia(CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Choroideremia is characterized by extensive loss of all retinal layers in the eyes.

DelveInsight’s, “Choroideremia Pipeline Insight, 2021” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

Some of Choroideremia Companies are:

  • 4D Molecular Therapeutics
  • Roche
  • Biogen
  • Curative Biotechnology
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

DelveInsight’s Choroideremia report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Choroideremia Key Products

  • 4D-110
  • RG 6367
  • BIIB111
  • Metformin
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

Current Choroideremia Treatment Scenario and Choroideremia Emerging Therapies:

  • How many companies are developing Choroideremia drugs?
  • How many Choroideremia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Choroideremia and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Choroideremia: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Choroideremia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Choroideremia Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

BIIB111: Biogen

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

4D110: 4D Molecular therapeutics

Drug profiles in the detailed report…..

Preclinical stage products

• Comparative Analysis

Metformin: Curative Biotechnology

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Choroideremia Key Companies

Choroideremia Key Products

Choroideremia- Unmet Needs

Choroideremia- Market Drivers and Barriers

Choroideremia- Future Perspectives and Conclusion

Choroideremia Analyst Views

Choroideremia Key Companies

Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/choroideremia-pipeline-insight

Categories